|Combination antiretroviral therapy and the risk of myocardial infarction|
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
|Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study|
S Collins, T Mertenskoetter, E Loeliger, R Tressler, I Weller, N Friis-Møller, ...
Archives of internal medicine 166 (15), 1632-1641, 2006
|Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study|
N Friis-Møller, R Weber, P Reiss, R Thiébaut, O Kirk, AA Monforte, ...
Aids 17 (8), 1179-1193, 2003
|Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration|
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
|Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients|
A Alberti, N Clumeck, S Collins, W Gerlich, J Lundgren, G Palu, P Reiss, ...
Journal of hepatology 42 (5), 615-624, 2005
|Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …|
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
|Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment|
Y Levy, C Lacabaratz, L Weiss, JP Viard, C Goujard, JD Lelièvre, F Boué, ...
The Journal of clinical investigation 119 (4), 997-1007, 2009
|Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination|
D Furman, BP Hejblum, N Simon, V Jojic, CL Dekker, R Thiébaut, ...
Proceedings of the National Academy of Sciences 111 (2), 869-874, 2014
|The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D: A: D Study|
MG Law, N Friis‐Møller, WM El‐Sadr, R Weber, P Reiss, ...
HIV medicine 7 (4), 218-230, 2006
|Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis|
JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ...
Jama 305 (13), 1327-1335, 2011
|Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study|
N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ...
European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010
|Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke|
DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ...
American journal of preventive medicine 20 (2), 16-66, 2001
|Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis|
E Arrivé, ML Newell, DK Ekouevi, ML Chaix, R Thiebaut, B Masquelier, ...
International journal of epidemiology 36 (5), 1009-1021, 2007
|Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy|
B Marin, R Thiébaut, HC Bucher, V Rondeau, D Costagliola, M Dorrucci, ...
AIDS (London, England) 23 (13), 1743, 2009
|Reduced bone mineral density in HIV-infected patients: prevalence and associated factors|
C Cazanave, M Dupon, V Lavignolle-Aurillac, N Barthe, S Lawson-Ayayi, ...
Aids 22 (3), 395-402, 2008
|Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America|
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
|Effectiveness of disease-management programs for improving diabetes care: a meta-analysis|
C Pimouguet, M Le Goff, R Thiébaut, JF Dartigues, C Helmer
Cmaj 183 (2), E115-E127, 2011
|Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999|
R Thiébaut, V Daucourt, P Mercié, DK Ekouévi, D Malvya, P Morlat, ...
Clinical Infectious Diseases 31 (6), 1482-1487, 2000
|Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need …|
S Lodi, A Phillips, G Touloumi, R Geskus, L Meyer, R Thiébaut, ...
Clinical infectious diseases 53 (8), 817-825, 2011
|Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized …|
Y Levy, I Sereti, G Tambussi, JP Routy, JD Lelievre, JF Delfraissy, ...
Clinical infectious diseases 55 (2), 291-300, 2012